Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic Results from the epicovideha registry /
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an i...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2024
|
| Sorozat: | HEMATOLOGICAL ONCOLOGY
42 No. 1 |
| Tárgyszavak: | |
| doi: | 10.1002/hon.3240 |
| mtmt: | 34434535 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/29092 |
| LEADER | 03174nab a2200409 i 4500 | ||
|---|---|---|---|
| 001 | publ29092 | ||
| 005 | 20240203113857.0 | ||
| 008 | 231215s2024 hu o 000 Angol d | ||
| 022 | |a 0278-0232 | ||
| 024 | 7 | |a 10.1002/hon.3240 |2 doi | |
| 024 | 7 | |a 34434535 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a Angol | ||
| 100 | 1 | |a Musto Pellegrino | |
| 245 | 1 | 0 | |a Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic |h [elektronikus dokumentum] : |b Results from the epicovideha registry / |c Musto Pellegrino |
| 260 | |c 2024 | ||
| 300 | |a 15 | ||
| 490 | 0 | |a HEMATOLOGICAL ONCOLOGY |v 42 No. 1 | |
| 520 | 3 | |a Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 × 109 /L was found to be protective. This data suggests that MM patients remain at risk of SARS-CoV-2 infection even in the vaccination era, but their clinical outcome, in terms of OS, has progressively improved throughout the different viral phases of the pandemic. | |
| 650 | 4 | |a Klinikai orvostan | |
| 700 | 0 | 2 | |a Salmanton-García Jon |e aut |
| 700 | 0 | 2 | |a Sgherza Nicola |e aut |
| 700 | 0 | 2 | |a Bergantim Rui |e aut |
| 700 | 0 | 2 | |a Farina Francesca |e aut |
| 700 | 0 | 2 | |a Glenthøj Andreas |e aut |
| 700 | 0 | 2 | |a Seval Guldane Cengiz |e aut |
| 700 | 0 | 2 | |a Weinbergerová Barbora |e aut |
| 700 | 0 | 2 | |a Bonuomo Valentina |e aut |
| 700 | 0 | 2 | |a Bilgin Yavuz M. |e aut |
| 700 | 0 | 2 | |a van Doesum Jaap |e aut |
| 700 | 0 | 2 | |a Jaksic Ozren |e aut |
| 700 | 0 | 2 | |a Víšek Benjamín |e aut |
| 700 | 0 | 2 | |a Falces‐Romero Iker |e aut |
| 700 | 0 | 2 | |a Piukovics Klára |e aut |
| 700 | 0 | 2 | |a et al. |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/29092/3/34434535_megjelent.pdf |z Dokumentum-elérés |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/29092/1/musto.pdf |z Dokumentum-elérés |